Type 1 Diabetes (requires specialized care)
To qualify for this peptide therapy, you must be in relatively good health, have realistic expectations for your treatment, and also be comfortable with the injection process
Contact your GP or prescribing clinician if you experience : Severe or persistent nausea and vomiting that prevents adequate fluid or food intake, as this may lead to dehydration Severe abdominal pain , particularly if sharp, constant, or localised to a specific area Signs of pancreatitis , including persistent severe pain in the upper abdomen that may radiate to the back, often accompanied by nausea and vomiting Blood in vomit or stools , which may appear red or have a dark, tar-like appearance Symptoms of gallbladder disease , such as pain in the upper right abdomen, particularly after eating fatty meals Unexplained fever alongside digestive symptoms Rapid ongoing weight loss with inability to maintain adequate hydration or nutrition Stop taking Saxenda and seek urgent medical attention (call 999 or attend A&E) if you develop : Severe, sudden-onset abdominal pain, especially if pancreatitis is suspected Persistent vomiting with inability to keep down any fluids Signs of severe dehydration (dizziness, confusion, very dark urine, no urination for 8+ hours) or concerns about acute kidney injury Allergic reaction symptoms (difficulty breathing, facial swelling, severe rash) For persistent but non-urgent sulphur burps , schedule a routine appointment with your GP if the symptom continues despite dietary modifications, significantly impacts your quality of life, or you have concerns about continuing Saxenda
But what about the cravings of a more romantic nature
Smaller employers often avoid some of the risk of health insurance losses by contracting with an insurer such as Blue Cross to assume the risk of huge, unforeseen spikes in claims
Baseline body weight in STEP 1, STEP 3, and STEP 8 was approximately 105 kg, and slightly lower (approximately 100 kg) in STEP 2, which focused on patients with type 2 diabetes and even lower in STEP 4 (approximately 96 kg), which featured a 20-week run-in where all patients received semaglutide before randomization
